Cherry (C3RY) Analyst Day 2025 summary
Event summary combining transcript, slides, and related documents.
Analyst Day 2025 summary
25 Nov, 2025Strategic restructuring and business realignment
Comprehensive reorganization in January 2025 consolidated sales and marketing for peripherals and centralized product management across Europe.
Switch production discontinued at Auerbach, with manufacturing shifted to China and Slovakia to address competitive disadvantages and reduce costs.
Auerbach site transformed into a development, logistics, and service hub for Europe, retaining strategic value.
Portfolio optimization in peripherals, reducing SKUs by 75% and focusing on high-margin, high-demand products, especially cordless and gaming.
New partner program and master distribution model launched to streamline go-to-market and improve profitability.
Financial performance and guidance
2024 revenue was EUR 110.4 million, down 13% year-over-year, with adjusted EBITDA at EUR -7 million due to inventory write-downs and impairments.
Q1 2025 revenue was EUR 25.3 million, 16% lower than Q1 2024, with an adjusted EBITDA margin of -8%.
Inventory levels reduced to EUR 50.4 million by March 2025, with trade working capital at EUR 51.8 million.
2025 guidance: group revenue of EUR 105–120 million and adjusted EBITDA margin of 3–6%, expecting margin recovery in H2 due to seasonality and restructuring benefits.
Financing facility with UniCredit extended to 2027, focusing on liquidity milestones rather than leverage covenants, with EUR 23m facility and scheduled repayments.
Market and operational highlights
Achieved over 70% market share in e-health new terminal sales; digital health segment remains a growth focus with SmartLink provider approval and SaaS opportunities.
Peripherals business saw strong market share gains in Germany and EU3 retail, reaching 23% by Q4 2024, but remains underpenetrated in the UK and France.
Shift from sell-in to sell-out models, with a focus on demand-driven sales, margin improvement, and channel/customer separation.
U.S. business impacted by tariffs and inventory challenges; new partner network established to reactivate growth.
Asia-Pacific outperformed expectations, with inventory reduction and a 22nd anniversary campaign planned to boost sales.
Latest events from Cherry
- 2025 revenue fell 15% to €94.3M, with cost cuts, margin recovery, and segment review ongoing.C3RY
Q4 20255 Mar 2026 - 2024 guidance targets €140m–€150m revenue and a 7–8% EBITDA margin, signaling a strong turnaround.C3RY
Investor presentation4 Feb 2026 - Revenue and EBITDA fell short, triggering cost cuts and a revised €120m 2024 outlook.C3RY
Investor presentation4 Feb 2026 - Streamlined for margin-driven growth, with €120M 2024 revenue forecast and €3.5M cost savings.C3RY
Investor presentation4 Feb 2026 - Restructuring, M&A, and operational streamlining target a return to growth and financial stability.C3RY
Investor presentation4 Feb 2026 - Digital Health & Solutions growth and cost controls support outlook despite margin pressure.C3RY
Q2 20243 Feb 2026 - Q3 2024 results missed expectations, triggering restructuring and a cut in full-year guidance.C3RY
Q3 2024 TU19 Jan 2026 - Revenue and margins fell, but Q4 free cash flow rose as restructuring targets 2025 recovery.C3RY
Q4 2024 TU26 Dec 2025 - 9M 2025 revenue down 16%, Q3 up 9.3% YoY; net loss widens amid restructuring.C3RY
Q3 2025 TU17 Nov 2025